Anti-LRRK2 antibody [UDD3 30(12)] - BSA and Azide free
- KO Validated
- RabMAb
- Recombinant
- What is this?
Be the first to review this product! Submit a review
|
(3 Publications)
Rabbit Recombinant Monoclonal LRRK2 antibody. Carrier free. Suitable for WB, ICC/IF and reacts with Human, Mouse samples. Cited in 3 publications.
View Alternative Names
PARK8, LRRK2, Leucine-rich repeat serine/threonine-protein kinase 2, Dardarin
- ICC/IF
Lab
Immunocytochemistry/ Immunofluorescence - Anti-LRRK2 antibody [UDD3 30(12)] - BSA and Azide free (AB170993)
Immunofluorescent staining of SH-SY5Y cells fixed and permeablized with 4% PFA and 0.1% Triton X 100 using purified ab133518 at a dilution of 1/200. An Alexa Fluor® 488 goat anti-rabbit was used as the secondary (ab150077, 1/400) and the sample was stained with DAPI. The negative control is shown in bottom right hand panel - for the negative control, purified ab133518 was used at a dilution of 1/200 followed by an Alexa Fluor® 594 goat anti-mouse antibody (ab150120) at a dilution of 1/500.
This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab133518).
- WB
Lab
Western blot - Anti-LRRK2 antibody [UDD3 30(12)] - BSA and Azide free (AB170993)
This data was developed using ab133518, the same antibody clone in a different buffer formulation.
Western blot : Rabbit Monoclonal[UDD3 30(12)] to LRRK2 ab133518 staining at 1/1000 dilution, shown in green; Mouse anti-CANX (ab238078) loading control staining at 1/20,000 dilution, shown in magenta. A band was observed at 268 kDa in Wild-type U-87 MG cell lysates with no signal observed at this size in LRRK2 knockout U-87 MG cell line. To generate this image, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 3pc Milk in TBS-0.1 % Tween® 20 (TBS-T) before incubation with primary antibodies overnight at 4 °C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times then imaged. Secondary antibodies used were Goat anti-Rabbit 800CW & Goat anti-Mouse 680RD at 1/20,000 dilution.
All lanes:
Western blot - Anti-LRRK2 antibody [UDD3 30(12)] (<a href='/en-us/products/primary-antibodies/lrrk2-antibody-udd3-3012-ab133518'>ab133518</a>) at 1/1000 dilution
Lane 1:
Wild-type U-87 MG at 20 µg
Lane 2:
Western blot - Human LRRK2 knockout U-87 MG cell line (ab306722) at 20 µg
Lane 3:
A549 at 20 µg
Lane 4:
HT-29 at 20 µg
Secondary
Lanes 1 - 4:
Goat anti-Rabbit 800CW at 1/20000 dilution
Lanes 1 - 4:
Goat anti-Mouse 680RD at 1/20000 dilution
Predicted band size: 286 kDa
Observed band size: 268 kDa,80 kDa
false
- WB
Lab
Western blot - Anti-LRRK2 antibody [UDD3 30(12)] - BSA and Azide free (AB170993)
This data was developed using ab133518, the same antibody clone in a different buffer formulation.
ab133518 was shown to react with LRRK2 in wild-type A549 cells in Western blot with loss of signal observed in a LRRK2 knockout cell line. Wild-type A549 and LRRK2 knockout cell lysates were subjected to SDS-PAGE. Membranes were blocked in 5% milk in TBST for 1 hr before incubation with ab133518 overnight at 4 °C at a 1/500 dilution. Blots were incubated with secondary antibodies at 0.2 µg/mL before imaging.
These data were provided by YCharOS Inc., an open science company with the mission of characterizing commercially available antibody reagents for all human proteins. Abcam and YCharOS are working together to help address the reproducibility crisis by enabling the life science community to better evaluate commercially available antibodies.
All lanes:
Western blot - Anti-LRRK2 antibody [UDD3 30(12)] (<a href='/en-us/products/primary-antibodies/lrrk2-antibody-udd3-3012-ab133518'>ab133518</a>) at 1/500 dilution
Lane 1:
Wild-type A549 lysate at 25 µg
Lane 2:
LRRK2 knock-out A549 lysate at 25 µg
false
- WB
Lab
Western blot - Anti-LRRK2 antibody [UDD3 30(12)] - BSA and Azide free (AB170993)
This WB data was generated using the same anti-LRRK2 antibody clone, UDD3 30(12), in a different buffer formulation (cat# ab133518).
Lane 1 : Wild-type A549 cell lysate (20 μg)
Lane 2 : LRRK2 knockout A549 cell lysate (20 μg)
Lane 3 : Wild-type MEF cell lysate (20 μg)
Lane 4 : LRRK2 knockout MEF cell lysate (20 μg)
Lanes 1 - 4 : Merged signal (red and green). Green - ab133518 observed at 238 kDa. Red - loading control, ab130007, observed at 124 kDa.
ab133518 was shown to specifically react with wild type A549 and MEF cell lines. No band was observed when knock out samples were used. Wild-type and LRRK2 knockout samples were subjected to SDS-PAGE. ab133518 and ab130007 (loading control to Vinculin) were diluted at 1/500 and 1/10000 dilution respectively and incubated overnight at 4C. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773 and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed ab216776 secondary antibodies at 1/10000 dilution for 1 hour at room temperature before imaging.
Wild-type and LRRK2 knockout MEF and A549 cells were provide as generous a gift from Professor Dario Alessi, MRC Protein Phosphorylation and Ubiquitination Unit (University of Dundee).
All lanes:
Western blot - Anti-LRRK2 antibody [UDD3 30(12)] (<a href='/en-us/products/primary-antibodies/lrrk2-antibody-udd3-3012-ab133518'>ab133518</a>)
Predicted band size: 286 kDa
false
Reactivity data
Product details
ab170993 is the carrier-free version of ab133518.
Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free batch production
For more information, read more on recombinant antibodies.
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar® is a trademark of Fluidigm Canada Inc.
Collaborations
This antibody was developed with support from The Michael J. Fox Foundation.
Properties and storage information
Form
Purification technique
Storage buffer
Shipped at conditions
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Storage information
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
LRRK2 interacts with cellular mechanisms by regulating cytoskeletal dynamics autophagy and vesicle trafficking. It is a part of a larger complex that includes other proteins involved in these processes. The kinase activity of LRRK2 plays an essential part in maintaining neuronal health and function. It influences the process of autophagy which is a way cells clean themselves by removing damaged components and recycling them.
Pathways
The action of LRRK2 is central to the mitogen-activated protein kinase (MAPK) and the mammalian target of rapamycin (mTOR) pathways. In these pathways LRRK2 interacts with other proteins such as mTOR and RPS6KB1. It modulates cellular processes like growth proliferation and response to stressors. Its kinase activity affects the phosphorylation state of targets within the pathways hence influencing biological outcomes like survival and apoptosis.
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
Target data
Publications (3)
Recent publications for all applications. Explore the full list and refine your search
NPJ Parkinson's disease 8:92 PubMed35853899
2022
Applications
Unspecified application
Species
Unspecified reactive species
Cells 9: PubMed32033496
2020
Applications
Unspecified application
Species
Unspecified reactive species
Cell cycle (Georgetown, Tex.) 18:2727-2741 PubMed31432728
2019
Applications
Unspecified application
Species
Unspecified reactive species
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com